By Bhanvi Satija and Patrick Wingrove(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's (NYSE:) weight-loss drug Zepbound led ...
Eli LillyLYLYIt posted better-than-expected third-quarter earnings on Thursday thanks to continued growth in sales of its anti-obesity drug Mounjaro, which ...